Geller, LT, et al. “Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.” Science, 2017, 357(6356), 1156-1160.
Wellington, S, et al.; “A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase.” Nat. Chem. Biol., 2017, 13, 943-950.
Corsello, SM, et al.; “The Drug Repurposing Hub: a next-generation drug library and information resource.” Nat. Med., 2017, 23, 405-408.
Law, JM, et al.; “Discovery of 8-Membered Ring Sulfonamides as Inhibitors of Oncogenic Mutant Isocitrate Dehydrogenase 1.” ACS Med. Chem. Lett., 2016, 7(10), 944-949.
Over, B, et al. “Structural and Conformational Determinants of Macrocycle Cell Permeability.” Nat. Chem. Biol., 2016, 12, 1065-1074.
Dockendorff, C, Falloon, PW, Pu, J et al. Benzo-fused lactams from a diversity-oriented synthesis (DOS) library as inhibitors of scavenger receptor BI (SR-BI)-mediated lipid uptake. Bioorg. Med. Chem. Lett. 2015; 25(10), 2100-2105.
Stephen Johnston, Ph.D.
Stephen Johnston is the associate director of operations at the Center for the Development of Therapeutics (CDoT) of the Broad Institute of MIT and Harvard. His role revolves around working with the scientific groups and therapeutic projects within CDoT to best enable the scientific work. This involves collaboratively looking at the people, space, finances, and other operational and strategic aspects around CDoT therapeutic projects and CDoT platform activities, e.g., compound management, analytical chemistry/ADME (absorption, distribution, metabolism, excretion), and high-throughput screening (HTS).
Johnston received his bachelor’s degree in chemistry from Davidson College, followed by a doctorate in analytical chemistry from the University of North Carolina at Chapel Hill. He joined the Broad Institute in 2007. His primary scientific areas of expertise are liquid chromatography–mass spectrometry of small molecules, purity assessment and purification, ADME, and maintenance and repair of analytical instrumentation. He has additional expertise in pharmacokinetics and high-throughput screening with mass spectrometric detection. He has been part of the organizing committee for the annual Boston Society HT-ADME conference since 2015, chairing the conference in 2019.
Contact Stephen Johnston via email at email@example.com.